Harpoon Therapeutics is developing a class of engineered proteins called T cell engagers that can direct the body’s own T cells to kill tumor cells.

from MarketWatch.com - Financial Services Industry News https://on.mktw.net/2ET4K6Q
via IFTTT
from MarketWatch.com - Financial Services Industry News https://on.mktw.net/2ET4K6Q
via IFTTT
Kommentare
Kommentar veröffentlichen